Skip to main content

Radiation Oncology

See Also:
The Beamline Bulletin

Expert Gallery Profiles

Submissions from 2017 2017

The role of radiation in treating glioblastoma: here to stay, Minesh Mehta

The Changing Role of Whole-Brain Radiotherapy: Demise or Time for Selective Usage?, Minesh Mehta

The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases, Minesh Mehta

A Multi-institutional Analysis of Trimodality Therapy for Esophageal Cancer in Elderly Patients, Michael Chuong and Minesh Mehta

A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas, Minesh Mehta

Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stage I disease : A multi-institutional treatment recommendation, Minesh Mehta

The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings, Michael Chuong

Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525, Minesh Mehta

Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer, Minesh Mehta and Michael Chuong

Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529, Andre Abitbol

An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825, Minesh Mehta

The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria, Minesh Mehta

Cost-effectiveness of prophylactic cranial irradiation with hippocampal avoidance in limited stage small cell lung cancer, Minesh Mehta

Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients, Minesh Mehta

Dosimetric and radiobiological impact of intensity modulated proton therapy and RapidArc planning for high-risk prostate cancer with seminal vesicles, Suresh Rana

Establishing Evidence-Based Indications for Proton Therapy: An Overview of Current Clinical Trials, Minesh Mehta

Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer, Minesh Mehta

Radiation Therapy for Liver Tumors: The State-of-the-art, Miguel Perez and Michael Chuong

Submissions from 2016 2016

Reply to M.C. Chamberlain, Minesh Mehta

Low Levels of Acute Toxicity Associated With Proton Therapy for Low-Grade Glioma: A Proton Collaborative Group Study, Minesh Mehta

Caloric restriction coupled with radiation decreases metastatic burden in triple negative breast cancer, Minesh Mehta

Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: a systematic review, Minesh Mehta

Stereotactic Radiosurgery for Treatment of Brain Metastases, Minesh Mehta

International Medical Graduates in Radiation Oncology: Historical Trends and Comparison With Other Medical Specialties, Minesh Mehta

Clinical ramifications of "genomic staging" of low-grade gliomas, Minesh Mehta

An overview of modern proton therapy, Minesh Mehta

HPV-Associated Oropharyngeal Cancer: Changing Treatment Paradigm & Prognosis, Andre Abitbol

Submissions from 2012 2012

Accelerated partial breast irradiation is safe and effective using intensity-modulated radiation therapy in selected early-stage breast cancer, Alan Lewin, Robert Derhagopian, Andre Abitbol, D Jay Wieczorek, Vivek Mishra, and Lourdes Moreno

Submissions from 2007 2007

Treatment of early non-small cell lung cancer, stage IA, by image-guided robotic stereotactic radioablation--CyberKnife, William Brown, Alan Lewin, and Andre Abitbol

Submissions from 2005 2005

Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol, Andre Abitbol, Alan Lewin, and Michael Troner

Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma, Andre Abitbol, Alan Lewin, and Michael Troner

Submissions from 2002 2002

Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol, Andre Abitbol, Alan Lewin, Michael Troner, and Maria-Amelia Rodrigues

Submissions from 1996 1996

Management of stage I-B, II-A, and II-B carcinoma of the cervix with high-dose-rate brachytherapy: initial results of an institutional clinical trial, Andre Abitbol and Alan Lewin

Submissions from 1992 1992

Stereotactic radiosurgery: dose-volume analysis of linear accelerator techniques, Christopher Serago, Alan Lewin, Andre Abitbol, Sergio Gonzalez-Arias, and Victor Marcial-Vega

Submissions from 1991 1991

Scattering effects on the dosimetry of iridium-192, Christopher Serago, Andre Abitbol, Alan Lewin, and Victor Marcial-Vega

Improved linac dose distributions for radiosurgery with elliptically shaped fields, Christopher Serago, Alan Lewin, Sergio Gonzalez-Arias, Andre Abitbol, and Victor Marcial-Vega

Stereotactic target point verification of an X ray and CT localizer, Christopher Serago, Alan Lewin, Sergio Gonzalez-Arias, and Andre Abitbol